Tag Archives: Deals

Big Biotech Gains Offset Big Pharma Losses

Big Pharma employment dropped by 3 percent in the decade 2003–2013, allaying fears that industry consolidation and restructuring would lead to significantly reduced headcounts and payrolls, a report by EP Vantage reveals. The report shows that when it comes to pharmaceutical industry jobs, Big Biotech and specialty drugmakers are growing in significance, more than offsetting the […]
Posted in Biotech, Deals, Global, Strategy | Also tagged , , , , | Leave a comment

The Urge to Merge: Dealmaking Lessons from Pharma History

By Cliff Kalb. The major pressures hindering pharmaceutical industry success have not changed—payer constraints on drug costs, R&D productivity, an increasingly risk-averse regulatory climate, generic encroachment, and negative public perceptions linked to reputation. Looking at the latest rendition of the Pharma 50, prescription drug revenue rankings for the top 10 major global players in 2013 […]
Posted in Deals, Global, Op-Ed, Strategy | Also tagged , , | Leave a comment

Rise in IPOs Eases Pharma's Investment Woes

Private equity and venture capital (PEVC) deal activity decreased from 1063 in 2010 to 480 in 2013, according to a new Frost & Sullivan report. And the pharma, biotech and healthcare equipment sectors experienced a much sharper decline in investor interest than the healthcare technology and provider segments, the report adds. But there is a […]
Posted in Biotech, Deals, Global, healthcare | Also tagged , , , , | Leave a comment

M&As and IPOs Shake Up CMO Industry

The CMO industry is undergoing a wave of ownership changes, including acquisitions, divestitures, and initial public offerings (IPOs). Ownership changes can lead to significant changes in a company’s strategy, focus, and prospects, so it is important for bio/pharmaceutical companies to review the implications of a key supplier’s change in ownership, writes Jim Miller. Recently announced […]
Posted in Deals, Manufacturing | Also tagged , , | Leave a comment

Actavis to Acquire Forest Labs for $25 Billion

Actavis and Forest Laboratories have entered into a definitive agreement under which Actavis will acquire Forest for a combination of cash and equity valued at approximately $25 billion or $89.48 per Forest share, Actavis announced in a press release. The transaction will combine the two high-growth specialty pharmaceutical companies, with combined annual revenues of more […]
Posted in Deals | Also tagged , , | Leave a comment
  • Categories

  • Meta